Fulcrum Therapeutics, Inc. (FULC) vs Ocugen, Inc. (OCGN)

Fulcrum Therapeutics, Inc. and Ocugen, Inc. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Ocugen, Inc. are of similar size ($280.0M and $275.9M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against −3.66%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −1,786.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Fulcrum Therapeutics, Inc. leads on 9 and Ocugen, Inc. on 5.

Valuation

Metric FULC OCGN Biotechnology median
P/E n/m n/m 8.50
P/S 3.37 57.68 9.71
P/B 0.90 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.43 n/m 0.64
EV/Sales (0.49) 36.22 9.21
Earnings yield (33.15%) (33.33%) (33.15%)
Free cash flow yield (23.60%) (23.10%) (25.50%)

Profitability

Metric FULC OCGN Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (1,504.43%) 0.00%
Net margin 0.00% (1,786.27%) 0.00%
Free cash flow margin 0.00% (1,332.36%) 0.00%
Return on equity (32.38%) 1,211.66% (56.36%)
Return on assets (30.75%) (92.03%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FULC OCGN Biotechnology median
Revenue growth (TTM) 1,939.80% (3.66%) 6.02%
EPS growth (last fiscal year) (637.50%) (15.00%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FULC OCGN Biotechnology median
Debt to equity 0.00 (0.11) 0.00
Current ratio 31.35 0.80 4.72
Net debt to EBITDA 4.23 (0.17) 0.96

Dividend

Metric FULC OCGN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FULC OCGN Biotechnology median
Market cap 280.01m 275.93m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack